Eli Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly will buy AurKa Pharma in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately held firm’s experimental cancer treatment for solid tumors. The deal is Lilly’s second in less than a week that aims to broaden its portfolio of lucrative cancer drugs. On Thursday, Lilly said it would buy Armo BioSciences for about $1.6 billion. AurKa Pharma will receive $110 million upfront and…

Read More